CN116098983A - Blood peptide composition and application thereof - Google Patents
Blood peptide composition and application thereof Download PDFInfo
- Publication number
- CN116098983A CN116098983A CN202211632071.4A CN202211632071A CN116098983A CN 116098983 A CN116098983 A CN 116098983A CN 202211632071 A CN202211632071 A CN 202211632071A CN 116098983 A CN116098983 A CN 116098983A
- Authority
- CN
- China
- Prior art keywords
- calf blood
- blood
- peptide
- calf
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 110
- 239000008280 blood Substances 0.000 title claims abstract description 110
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 80
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 244000309466 calf Species 0.000 claims abstract description 91
- 206010010774 Constipation Diseases 0.000 claims abstract description 37
- 230000000968 intestinal effect Effects 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 210000000601 blood cell Anatomy 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 238000002156 mixing Methods 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 25
- 210000002381 plasma Anatomy 0.000 claims description 24
- 238000010438 heat treatment Methods 0.000 claims description 23
- 239000011259 mixed solution Substances 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- 102000001554 Hemoglobins Human genes 0.000 claims description 20
- 108010054147 Hemoglobins Proteins 0.000 claims description 20
- 108090000526 Papain Proteins 0.000 claims description 17
- 239000004365 Protease Substances 0.000 claims description 17
- 230000013872 defecation Effects 0.000 claims description 17
- 229940055729 papain Drugs 0.000 claims description 17
- 235000019834 papain Nutrition 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 13
- 108010007119 flavourzyme Proteins 0.000 claims description 11
- 230000030136 gastric emptying Effects 0.000 claims description 11
- 230000003301 hydrolyzing effect Effects 0.000 claims description 9
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- 239000000811 xylitol Substances 0.000 claims description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 7
- 235000010447 xylitol Nutrition 0.000 claims description 7
- 229960002675 xylitol Drugs 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 230000008855 peristalsis Effects 0.000 claims description 6
- 241000221377 Auricularia Species 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 29
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 17
- 230000007062 hydrolysis Effects 0.000 description 15
- 238000006460 hydrolysis reaction Methods 0.000 description 15
- 238000001035 drying Methods 0.000 description 14
- 241000283690 Bos taurus Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 239000008213 purified water Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 238000004108 freeze drying Methods 0.000 description 10
- 238000007710 freezing Methods 0.000 description 10
- 230000008014 freezing Effects 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 238000005303 weighing Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000012535 impurity Substances 0.000 description 9
- 238000001816 cooling Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000000108 ultra-filtration Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 235000015165 citric acid Nutrition 0.000 description 6
- 238000010612 desalination reaction Methods 0.000 description 6
- 238000001728 nano-filtration Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000219315 Spinacia Species 0.000 description 5
- 235000009337 Spinacia oleracea Nutrition 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000012907 honey Nutrition 0.000 description 5
- 239000000413 hydrolysate Substances 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 229940072113 onion extract Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- 238000009777 vacuum freeze-drying Methods 0.000 description 5
- 206010016100 Faeces discoloured Diseases 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000005176 gastrointestinal motility Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 238000000859 sublimation Methods 0.000 description 4
- 230000008022 sublimation Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 244000028550 Auricularia auricula Species 0.000 description 1
- 235000000023 Auricularia auricula Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/345—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of blood proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
- A23L21/25—Honey; Honey substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Water Supply & Treatment (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the technical field of biology, in particular to a blood peptide composition and application thereof. The invention provides a calf blood peptide composition and application thereof in preparing products for improving intestinal environment and/or relieving constipation, which have the advantages of good effect of improving intestinal environment and relieving constipation, small molecular weight, easy absorption by organisms, mild effect and obvious curative effect compared with the traditional medicine treatment.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a blood peptide composition and application thereof.
Background
Research shows that animal blood contains rich protein, trace elements, amino acids and other nutritive matters essential to human body, and is called liquid meat. Since the beginning of the 90 s of the last century, animal slaughter and meat yield in China have steadily kept the world in front, and animal blood resources are rich. The total bleeding amount of the cattle was 4.2% of the weight of the live cattle, and the protein content of the fresh cattle blood was 17.3%. At present, bovine blood research is mainly in two directions, namely deproteinized calf blood extract containing inorganic matters and micromolecular organic matters, which is obtained by physical modes such as deproteinization, ultrafiltration or dialysis, and micromolecular peptide which is easy to absorb and has good activity is obtained by hydrolyzing macromolecular proteins in blood by using a biological enzymolysis technology. The former process is mature, and related products have been steadily applied in clinical treatment. The adoption of biological enzymolysis technology to improve the utilization rate of blood protein has been a hotspot of research at home and abroad, and single enzyme is used, and along with the deep research, the modes of multi-enzyme composite hydrolysis or bacteria-enzyme combined hydrolysis and the like are gradually adopted. The difference of bovine blood proteolytic technology can directly influence key indexes such as content, activity, purity and the like of terminal small molecule peptide, and continuous optimization research is needed to obtain technology update and upgrade.
The calf blood peptide is mature and applied to clinical medicines and functional health products, the efficacy field relates to the treatment of brain and nervous system, vascular, radioactive injury, ulcer, burn, eyes and other diseases, and the calf blood peptide has certain effects of iron deficiency blood enriching, immune activity enhancement, fatigue resistance and the like. In addition, animal blood is often used to remove in vivo dust, enterotoxins, and other waste materials in traditional eating methods, but bovine blood peptides are currently relatively less systematically studied in this field.
Constipation is one of the common manifestations of intestinal diseases, and investigation shows that the prevalence rate of chronic constipation for adults in China is 4.0% -10.0%, the prevalence rate of chronic constipation for people over 70 years old is 23.0% and the prevalence rate of chronic constipation for people over 80 years old is 38.0% along with the increase of ages. Constipation can be classified into mild, moderate and severe constipation, and mild constipation is generally relieved by adjusting dietary structure and work and rest rules, but the effect is not significant, so that the conditioning period is relatively longer; moderate and severe depends on drug therapy or surgical therapy, and the method often has side effects to affect the health of human body. Therefore, the product for improving the intestinal canal and defecation problems of constipation patients by providing a gentle and efficient method has important practical significance.
Disclosure of Invention
In view of the above, the blood peptide composition and the application thereof provided by the invention have the advantages of good effects of improving intestinal environment and relieving constipation, small molecular weight, easy absorption by organisms, mild effect and obvious curative effect compared with the traditional medicine treatment.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides application of calf blood peptide in preparing a product for improving intestinal environment and/or relieving constipation; the product comprises a medicament or a food product.
In some embodiments of the invention, the relieving constipation in the above application comprises:
(I) Accelerating gastric emptying; and/or
(II) accelerating intestinal peristalsis; and/or
(III) accelerating the first defecation time; and/or
(IV) increasing total defecation; and/or
(V) improving the water content of the excrement.
In some embodiments of the present invention, the method for preparing calf blood peptide in the above application comprises the following steps:
step (1): collecting calf blood, crushing blood cells in the calf blood, and mixing with blood plasma in the calf blood to obtain a hemoglobin mixed solution;
step (2): mixing the hemoglobin mixed solution obtained in the step (1) with papain, stirring, hydrolyzing, heating and preserving heat to obtain a primary enzymolysis solution, mixing the primary enzymolysis solution with flavourzyme, hydrolyzing, heating and preserving heat, filtering and concentrating to obtain the calf blood peptide.
In some embodiments of the invention, the method of preparation in the above application further comprises the step of lyophilizing the calf blood peptide after step (2).
In some embodiments of the invention, the papain in step (2) of the preparation method in the above application has an enzyme activity of 200.5U/g.
In some embodiments of the present invention, the weight ratio of the papain to the hemoglobin mixture in step (2) in the preparation method in the above application is 1:1000 to 3:1000.
In some embodiments of the present invention, the temperature of the first hydrolysis in step (2) in the preparation method in the above application is 45 to 65 ℃.
In some embodiments of the present invention, the time for the first hydrolysis in step (2) in the preparation method in the above application is 2 to 4 hours.
In some embodiments of the present invention, the temperature of the first heat preservation in step (2) in the preparation method in the above application is 95 to 100 ℃.
In some embodiments of the present invention, the first time of the heating and maintaining in step (2) in the preparation method in the above application is 15 to 30 minutes.
In some embodiments of the invention, the flavourzyme in step (2) of the method of preparation in the above application has an enzyme activity of 2.3 ten thousand U/g.
In some embodiments of the present invention, the weight ratio of the papain in step (2) to the primary enzymatic hydrolysate in the preparation method in the above application is 1:100 to 1:50.
In some embodiments of the present invention, the temperature of the second hydrolysis in step (2) in the preparation method in the above application is 45 to 60 ℃.
In some embodiments of the invention, the time of the second hydrolysis in step (2) in the preparation method in the above application is 2 to 4 hours.
In some embodiments of the present invention, the temperature of the second heat preservation in step (2) in the preparation method in the above application is 85 to 95 ℃.
In some embodiments of the present invention, the second heating and maintaining time in step (2) in the preparation method in the above application is 15 to 30min.
The present invention also provides a composition comprising: calf blood peptide, auricularia, bulbus Allii Cepae and herba Spinaciae, and acceptable adjuvants.
In some embodiments of the invention, the above composition comprises: calf blood peptide, auricularia extract, bulbus Allii Cepae extract, herba Spinaciae extract, mel, citric acid and xylitol, and acceptable adjuvants.
In some embodiments of the present invention, the above composition comprises, by weight, per 1000 g:
the invention also provides application of the composition in preparation of a product for improving intestinal environment and/or relieving constipation; the product comprises a medicament or a food product.
In some embodiments of the invention, the relieving constipation in the above application comprises:
(I) Accelerating gastric emptying; and/or
(II) accelerating intestinal peristalsis; and/or
(III) accelerating the first defecation time; and/or
(IV) increasing total defecation; and/or
(V) improving the water content of the excrement.
In some embodiments of the present invention, the method for preparing calf blood peptide in the composition in the above application comprises the steps of:
step (1): collecting calf blood, crushing blood cells in the calf blood, and mixing with blood plasma in the calf blood to obtain a hemoglobin mixed solution;
step (2): mixing the hemoglobin mixed solution obtained in the step (1) with papain, stirring, hydrolyzing, heating and preserving heat to obtain a primary enzymolysis solution, mixing the primary enzymolysis solution with flavourzyme, hydrolyzing, heating and preserving heat, filtering and concentrating to obtain the calf blood peptide.
In some embodiments of the invention, the method of preparation in the above application further comprises the step of lyophilizing the calf blood peptide after step (2).
In some embodiments of the invention, the papain in step (2) of the preparation method in the above application has an enzyme activity of 200.5U/g.
In some embodiments of the present invention, the weight ratio of the papain to the hemoglobin mixture in step (2) in the preparation method in the above application is 1:1000 to 3:1000.
In some embodiments of the present invention, the temperature of the first hydrolysis in step (2) in the preparation method in the above application is 45 to 65 ℃.
In some embodiments of the present invention, the time for the first hydrolysis in step (2) in the preparation method in the above application is 2 to 4 hours.
In some embodiments of the present invention, the temperature of the first heat preservation in step (2) in the preparation method in the above application is 95 to 100 ℃.
In some embodiments of the present invention, the first time of the heating and maintaining in step (2) in the preparation method in the above application is 15 to 30 minutes.
In some embodiments of the invention, the flavourzyme in step (2) of the method of preparation in the above application has an enzyme activity of 2.3 ten thousand U/g.
In some embodiments of the present invention, the weight ratio of the papain in step (2) to the primary enzymatic hydrolysate in the preparation method in the above application is 1:100 to 1:50.
In some embodiments of the present invention, the temperature of the second hydrolysis in step (2) in the preparation method in the above application is 45 to 60 ℃.
In some embodiments of the invention, the time of the second hydrolysis in step (2) in the preparation method in the above application is 2 to 4 hours.
In some embodiments of the present invention, the temperature of the second heat preservation in step (2) in the preparation method in the above application is 85 to 95 ℃.
In some embodiments of the present invention, the second heating and maintaining time in step (2) in the preparation method in the above application is 15 to 30min.
The invention also provides a medicine or food, comprising the composition and acceptable auxiliary materials, auxiliary agents or additives.
The composition of the invention has the following effects:
1. animal experiments show that the compound product has good effects of improving intestinal environment and relieving constipation, has small molecular weight and is easy to be absorbed by organisms;
2. according to the invention, whole calf blood is taken as a raw material, and blood cells are separated and crushed independently in the process, so that not only is nutrient substances of calf blood reserved to the greatest extent, but also effective components in the blood cells are released to the greatest extent, and the biological activity of calf blood peptide is improved;
3. compared with traditional medicine treatment, the invention has the characteristics of mild effect and obvious curative effect, and the product has high application and industrialization degree and can be expected to have considerable economic benefit.
Detailed Description
The invention discloses a blood peptide composition and application thereof, and a person skilled in the art can refer to the content of the blood peptide composition and can properly improve the technological parameters. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included in the present invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that variations and modifications can be made in the methods and applications described herein, and in the practice and application of the techniques of this invention, without departing from the spirit or scope of the invention.
The invention aims at improving intestinal tracts and defecation problems of constipation patients by a mild and efficient method, and provides a blood peptide composition for improving intestinal tract environments and relieving constipation.
The invention aims to provide a blood peptide composition for improving intestinal environment and relieving constipation, which is prepared by compounding calf blood peptide, black fungus extract, onion extract, spinach extract, honey, citric acid and xylitol, so as to obtain an effect product which is daily edible for people and is used for improving constipation and improving life happiness, further fill up the study blank of the calf blood peptide in the aspect of gastrointestinal tract and provide a new direction for the innovation study of the calf blood peptide.
The invention mainly provides a calf blood peptide composition and a preparation method thereof.
The technical scheme adopted by the invention is as follows:
preparation of calf blood peptide:
(1) Pretreatment of raw materials: collecting and disrupting calf blood cells, and mixing with plasma
Adding 4% sodium citrate into 6 month-old cattle blood which is qualified by inspection and quarantine, stirring, centrifuging, respectively collecting blood cells and blood plasma, standing the blood plasma for standby, washing blood cells at least 3 times with 0.9% physiological saline, adding equal amount of purified water, stirring at high speed to swell and crush cells, releasing cell contents, repeatedly freezing and thawing for 3 times, adding blood plasma, and uniformly mixing to obtain hemoglobin mixed solution.
(2) Biological enzyme extraction: hydrolysis by complex enzymes
Heating the hemoglobin mixed solution to 45-65 ℃ in a water bath, adding papain accounting for 0.1-0.3% of the weight of the mixed solution, stirring and reacting for 2-4 hours, preserving heat for 15-30 minutes at 95-100 ℃ after the reaction is finished, adjusting the temperature to 45-60 ℃, adding flavourzyme accounting for 1-2% of the weight of the mixed solution, continuing to react for 2-4 hours, heating to 85-95 ℃ after the reaction is finished, and preserving heat for 15-30 minutes to obtain the calf blood enzymatic hydrolysate.
Papain: the activity of the enzyme is measured to be 200.5 ten thousand U/g by Nanning Pang Bo biological engineering Co., ltd;
flavourzyme: the enzyme activity was measured at 2.3U/g by Nanning Pang Bo Bio-engineering Co., ltd.
(3) Filtering and concentrating: ultra-filtration impurity removal by multistage filter membrane, nanofiltration, desalination and concentration
And (3) respectively carrying out series ultrafiltration on the calf blood enzymolysis liquid through a filter membrane of 20K/10K/5kDa, and then carrying out nanofiltration desalination to obtain calf blood peptide concentrated solution.
(4) And (3) drying: vacuum freeze drying
Loading the concentrated solution into a sample tray, pre-cooling in a refrigerator for 30min, and then placing into a vacuum freeze dryer for freeze drying according to a preset freeze drying curve, namely: freezing (temperature: about-40 to-50 ℃ and pressure: about 13 Pa) to form a solid, sublimating (temperature: about-10 to-20 ℃ and pressure: about 1.3 Pa), and finally drying (30 to 40 ℃) to obtain the calf blood peptide dry powder.
(II) preparation of calf blood peptide composition:
the calf blood peptide powder is used as a main raw material and is compounded with black fungus extract (standard number: Q/TRG077, manufacturer: han Zhongzhong natural cereal biotechnology Co., ltd.), onion extract (standard number: Q/TYCW 00005S, manufacturer: siam Biotechnology Co., ltd.), spinach extract (standard number: Q/TRG023, manufacturer: han Zhongzhong natural cereal biotechnology Co., ltd.), honey (standard number: Q/TYF 0001S, manufacturer: zhejiang Eve bee hive Co., ltd.), citric acid and xylitol, wherein the weight percentages of raw materials and auxiliary materials are: 10 to 20 percent of calf blood peptide, 2.0 to 5.0 percent of black fungus extract, 0.2 to 0.3 percent of onion extract, 1.5 to 2.5 percent of spinach extract, 15 to 30 percent of honey, 0.5 to 1.5 percent of citric acid and 5 to 10 percent of xylitol.
Unless otherwise specified, the raw materials, reagents, consumables and instruments involved in the present invention are all commercially available and commercially available.
The invention is further illustrated by the following examples:
example 1: preparation of calf blood peptide
Experiment group 1:
pretreatment of raw materials: collecting and disrupting calf blood cells, and mixing with plasma
Taking 50L of 6 month old fresh cattle blood which is qualified through inspection and quarantine, adding 3L of 4% sodium citrate, slowly and uniformly stirring, centrifuging at 3500 rpm for 15min at 2-8 ℃, separating bleeding cells and plasma, and standing the plasma for later use. The blood cells were washed with an equal amount of 0.9% physiological saline, centrifuged to remove the supernatant, and the procedure was repeated 3 times. Weighing blood cells, diluting with purified water, stirring at 600 rpm to break up blood cells, releasing content, freezing and thawing at-18deg.C and 6deg.C for 3 times, adding plasma, and mixing to obtain hemoglobin mixture.
Biological enzyme extraction: hydrolysis by complex enzymes
Heating the hemoglobin mixed solution to 45 ℃ in a water bath, adding papain accounting for 0.1% of the weight of the mixed solution, stirring and reacting for 2 hours, after the reaction is finished, preserving heat for 15 minutes at 95 ℃, adjusting the temperature to 45 ℃, adding flavourzyme accounting for 1% of the weight of the mixed solution, continuing to react for 2 hours, and after the reaction is finished, heating to 85 ℃, preserving heat for 15 minutes, thus obtaining the calf blood enzymatic hydrolysate.
Filtering and concentrating: ultra-filtration impurity removal by multistage filter membrane, nanofiltration, desalination and concentration
Ultrafiltering the enzymolysis liquid with 20K/10K/5kDa filter membrane to eliminate macromolecular impurity, and nanometer filtering to eliminate salt to obtain concentrated calf blood peptide liquid.
And (3) drying: vacuum freeze drying
Loading the concentrated solution into a sample tray, pre-cooling in a refrigerator for 30min, and then placing into a vacuum freeze dryer (LYO-7.5, shanghai Dongfulong technology Co., ltd.) for freeze-drying according to a preset freeze-drying curve, namely: freezing to solid state at about-40deg.C under 13Pa, sublimation drying (about-10deg.C under 1.3 Pa), and final drying at about 30deg.C to obtain cattle blood peptide dry powder 835g with extraction rate of 1.67% and activity of 21.5%.
Experiment group 2:
pretreatment of raw materials: collecting and disrupting calf blood cells, and mixing with plasma
Taking 50L of 6 month old fresh cattle blood which is qualified through inspection and quarantine, adding 3L of 4% sodium citrate, slowly and uniformly stirring, centrifuging at 3500 rpm for 15min at 2-8 ℃, separating bleeding cells and plasma, and standing the plasma for later use. The blood cells were washed with an equal amount of 0.9% physiological saline, centrifuged to remove the supernatant, and the procedure was repeated 3 times. Weighing blood cells, diluting with purified water, stirring at 600 rpm to break up blood cells, releasing content, freezing and thawing at-18deg.C and 6deg.C for 3 times, adding plasma, and mixing to obtain hemoglobin mixture.
Biological enzyme extraction: hydrolysis by complex enzymes
Heating the hemoglobin mixed solution to 55 ℃ in a water bath, adding papain accounting for 0.2% of the weight of the mixed solution, stirring and reacting for 3 hours, after the reaction is finished, preserving heat for 20 minutes at 95 ℃, adjusting the temperature to 50 ℃, adding flavourzyme accounting for 1.5% of the weight of the mixed solution, continuing to react for 3 hours, and after the reaction is finished, heating to 90 ℃, preserving heat for 20 minutes to obtain the calf blood enzymatic hydrolysate.
Filtering and concentrating: ultra-filtration impurity removal by multistage filter membrane, nanofiltration, desalination and concentration
Ultrafiltering the enzymolysis liquid with 20K/10K/5kDa filter membrane to eliminate macromolecular impurity, and nanometer filtering to eliminate salt to obtain concentrated calf blood peptide liquid.
And (3) drying: vacuum freeze drying
Loading the concentrated solution into a sample tray, pre-cooling in a refrigerator for 30min, and then placing into a vacuum freeze dryer (LYO-7.5, shanghai Dongfulong technology Co., ltd.) for freeze-drying according to a preset freeze-drying curve, namely: freezing to solid state at about-45deg.C under 13Pa, sublimation drying (about-15deg.C under 1.3 Pa), and final drying at about 35deg.C to obtain 946g calf blood peptide dry powder with extraction rate of 1.88% and activity of 24.8%.
Experiment group 3:
pretreatment of raw materials: collecting and disrupting calf blood cells, and mixing with plasma
Taking 50L of 6 month old fresh cattle blood which is qualified through inspection and quarantine, adding 3L of 4% sodium citrate, slowly and uniformly stirring, centrifuging at 3500 rpm for 15min at 2-8 ℃, separating bleeding cells and plasma, and standing the plasma for later use. The blood cells were washed with an equal amount of 0.9% physiological saline, centrifuged to remove the supernatant, and the procedure was repeated 3 times. Weighing blood cells, diluting with purified water, stirring at 600 rpm to break up blood cells, releasing content, freezing and thawing at-18deg.C and 6deg.C for 3 times, adding plasma, and mixing to obtain hemoglobin mixture.
Biological enzyme extraction: hydrolysis by complex enzymes
Heating the hemoglobin mixed solution to 65 ℃ in a water bath, adding papain accounting for 0.3% of the weight of the mixed solution, stirring and reacting for 4 hours, after the reaction is finished, preserving the heat for 30 minutes at 100 ℃, adjusting the temperature to 60 ℃, adding flavourzyme accounting for 2% of the weight of the mixed solution, continuing to react for 4 hours, and after the reaction is finished, heating to 95 ℃ and preserving the heat for 30 minutes.
Filtering and concentrating: ultra-filtration impurity removal by multistage filter membrane, nanofiltration, desalination and concentration
Ultrafiltering the enzymolysis liquid with 20K/10K/5kDa filter membrane to eliminate macromolecular impurity, and nanometer filtering to eliminate salt to obtain concentrated calf blood peptide liquid.
And (3) drying: vacuum freeze drying
Loading the concentrated solution into a sample tray, pre-cooling in a refrigerator for 30min, and then placing into a vacuum freeze dryer (LYO-7.5, shanghai Dongfulong technology Co., ltd.) for freeze-drying according to a preset freeze-drying curve, namely: freezing to solid state at about-50deg.C under 13Pa, sublimation drying (about-20deg.C under 1.3 Pa), and final drying at about 40deg.C to obtain calf blood peptide dry powder 860g with extraction rate of 1.72% and activity of 22.9%.
Experiment group 4:
preparing calf blood peptide by papain:
pretreatment of raw materials: collecting and disrupting calf blood cells, and mixing with plasma
Taking 50L of 6 month old fresh cattle blood which is qualified through inspection and quarantine, adding 3L of 4% sodium citrate, slowly and uniformly stirring, centrifuging at 3500 rpm for 15min at 2-8 ℃, separating bleeding cells and plasma, and standing the plasma for later use. The blood cells were washed with an equal amount of 0.9% physiological saline, centrifuged to remove the supernatant, and the procedure was repeated 3 times. Weighing blood cells, diluting with purified water, stirring at 600 rpm to break up blood cells, releasing content, freezing and thawing at-18deg.C and 6deg.C for 3 times, adding plasma, and mixing to obtain hemoglobin mixture.
Biological enzyme extraction: hydrolysis by single enzymes
Heating the hemoglobin mixed solution to 55 ℃ in a water bath, adding papain accounting for 0.2% of the weight of the mixed solution, stirring and reacting for 3 hours, and preserving heat for 20 minutes at 95 ℃ after the reaction is finished to obtain calf blood enzymolysis liquid.
Filtering and concentrating: ultra-filtration impurity removal by multistage filter membrane, nanofiltration, desalination and concentration
Ultrafiltering the enzymolysis liquid with 20K/10K/5kDa filter membrane to eliminate macromolecular impurity, and nanometer filtering to eliminate salt to obtain concentrated calf blood peptide liquid.
And (3) drying: vacuum freeze drying
Loading the concentrated solution into a sample tray, pre-cooling in a refrigerator for 30min, and then placing into a vacuum freeze dryer (LYO-7.5, shanghai Dongfulong technology Co., ltd.) for freeze-drying according to a preset freeze-drying curve, namely: freezing to solid state at about-45deg.C under 13Pa, sublimation drying (about-15deg.C under 1.3 Pa), and final drying at about 35deg.C to obtain calf blood peptide dry powder 510g with extraction rate of 1.02% and activity of 15.6%.
Quality detection is carried out on the calf blood peptides prepared in the experimental groups 1-4, and comparison analysis is carried out on the calf blood peptide technical indexes of different processes, and relevant results are shown in the table 1 and the table 2 respectively:
table 1: quality detection results of calf blood peptides prepared by each experimental group
Table 2: key quality index comparison table of calf blood peptide of each experimental group
The comparison in the experimental groups 1 to 3 shows that the calf blood peptide prepared by the invention has better quality parallelism and stable process; compared with experimental group 4, the calf blood peptide prepared in the invention is a comparison process in the aspects of protein content, polypeptide content, product activity, extraction rate and the like.
Example 2: experimental study for preparing calf blood peptide composition, improving intestinal environment and relieving constipation
Preparation of calf blood peptide composition
(1) Preparing required raw materials and auxiliary materials according to a batching table in the table 3;
table 3: calf blood peptide compound product batching table
(2) Preparation of blood peptide complex product sample 1: placing 250mL of purified water into a 1L container, heating to 50 ℃, respectively weighing 100.0g of calf blood peptide powder, 20.0g of black fungus extract, 2.0g of onion extract, 15.0g of spinach extract and 150.0g of honey, sequentially adding and stirring uniformly to obtain a solution A; taking another 50mL beaker, adding 30mL of purified water, weighing 5.0g of citric acid and 50.0g of xylitol, sequentially adding and stirring to dissolve to obtain a solution B; and (3) mixing the solution A and the solution B, weighing 1000g by using a purified water gauge, uniformly mixing, placing in a high-pressure steam sterilizer, sterilizing for 30min at 100 ℃, cooling, and packaging into 20mL ultraviolet sterilized glass bottles, wherein the total amount of the calf blood peptide compound product is 48 bottles.
(3) According to the operation procedure in (2), sample 2 (46 bottles), sample 3 (48 bottles) and sample 4 (47 bottles) of calf blood peptide complex products are prepared according to the amount of each raw and auxiliary material in Table 3.
(4) Sample 5 (without calf blood peptide): placing 250mL of purified water into a 1L container, heating to 50deg.C, respectively weighing 50.0g of Auricularia auricula-judae extract, 3.0g of onion extract, 25.0g of spinach extract and 300.0g of honey, sequentially adding and stirring to obtain solution A; taking another 50mL beaker, adding 30mL of purified water, weighing 15.0g of citric acid and 100.0g of xylitol, sequentially adding and stirring to dissolve to obtain a solution B; and (3) combining the solution A and the solution B, weighing 1000g by using a purified water gauge, uniformly mixing, placing in a high-pressure steam sterilizer, sterilizing for 30min at 100 ℃, cooling, and packaging into 25mL ultraviolet sterilized glass bottles, wherein the weight of the solution A and the solution B is 20 g/bottle, thus obtaining a negative control product 46 bottles without calf blood peptide.
Experimental study on improving intestinal environment and relieving constipation of calf blood peptide compound product
SPF-class Kunming mice, 18-22 g,80 mice, randomly divided into 8 groups of blank control group, negative control group, positive control group (magnesium sulfate 5 g/kg) and test group (calf blood peptide compound product 1-4, without calf blood peptide sample), 10 mice each. On days 1-4, the blank control group is fed with conventional feed, and other control groups and test groups are fed with rice and water is forbidden to establish a constipation model. On days 5-7, each group is fed with conventional feed, wherein the positive control group is filled with gastric magnesium sulfate, the test group is respectively filled with gastric calf blood compound products 1-4 and samples (10 mL/kg) without calf blood peptide, and the blank and negative control groups are filled with normal saline with the same amount of gastric juice for 1 time per day. On day 8, each group of mice was first perfused with a gastric carbon powder suspension (10 mL/kg), then the positive control group and the test group were given the corresponding test diet, and the blank and negative control groups were given an equal amount of physiological saline, 1 time each. Recording the first black stool time, total stool number and black stool number in 6 hours of each mouse, and measuring the water content and dry weight of the excrement; the cervical dislocation of each group of mice is killed, the whole stomach tissue is taken, and the stomach whole mass and the net mass are weighed; the mesentery is separated, the intestinal canal is cut, the total length of the small intestine and the advancing length of the carbon powder are measured, and the gastric emptying rate and the small intestine advancing rate are calculated.
Gastric emptying rate = 1- (stomach full mass-stomach net mass)/0.6
Small intestine propulsion = carbon end propulsion length/small intestine total length
The defecation parameters and gastrointestinal motility of each group of mice are shown in tables 4 to 7:
table 4: influence of calf blood peptide compound product on constipation mouse defecation parameters
Table 5: comparison of defecation parameters of mice of each group (n,%)
Wherein: comparison with the blank control group. The remaining groups were compared to the negative control group.
As shown in tables 4 and 5, compared with the blank control group, the weight of the mice in the negative control group is obviously reduced (n= -23.65%), the first-case black stool time is obviously increased (n=87.06%), the number of black stools in 6 hours (n= -29.49%), the total number of stools (n= -26.03%) and the dry weight of excrement (n= -26.92%), and the water content of excrement is obviously reduced (n= -34.61%), which indicates that the desiccation model is successfully prepared. Compared with the negative control, the first-case excrement blackening time of the test group 5 is slightly reduced, the excrement water content is slightly increased, the first-case excrement blackening time of the other administration groups is obviously reduced (n= -37% -46%), the number of black excrement in 6 hours (n=13% -32%), the total excrement (n=13% -30%) and the excrement water content (n=11% -56%) are obviously increased. The results show that the calf blood peptide compound product can effectively shorten the first defecation time of a constipation mouse and increase the total defecation amount and the fecal water content, wherein the sample without the calf blood peptide has a certain positive effect on the defecation time and the fecal water content of the mouse.
Table 6: effect of calf blood peptide composition on gastrointestinal motility in constipation mice
Table 7: comparison of gastrointestinal motility parameters (n,%)
Wherein: comparison with the blank control group. The remaining groups were compared to the negative control group.
As can be seen from tables 6 and 7, compared with the blank control group, the gastric emptying rate (n= -21.43%) and the carbon end propulsion rate (n= -37.46%) of the mice in the negative control group are all significantly reduced, which indicates that the gastrointestinal motility of the mice in the model is significantly reduced; compared with the negative control, the gastric emptying rate and the carbon end propulsion rate of the test group 5 are slightly increased, and the gastric emptying rate (n=11-24%) and the carbon end propulsion rate (n=26-56%) of the mice in the positive control group and the test groups are obviously increased, so that the calf blood peptide compound product can accelerate gastric emptying and intestinal peristalsis of the constipation mice.
Is influenced by modern work and life modes (long-term sitting, staying up, small exercise amount and the like), eating habits (spicy and greasy food, small meat and vegetables, small water intake and the like), and the gastrointestinal tract function of people is easy to be disturbed, and one of the obvious characteristics is constipation. The research is mainly based on the conditions to build a mouse constipation model, and experimental researches show that the calf blood peptide compound product can remarkably improve the defecation parameters, gastric emptying and intestinal peristalsis conditions of a constipation mouse and effectively relieve constipation. The experimental results of the test groups 1, 2 and 3, the test groups 2 and 4 and the test groups 3 and 4 are compared and analyzed respectively, and the result of the comprehensive comparison test group 5 shows that the calf blood peptide plays a dominant role in improving the intestinal environment and relieving constipation.
From the results, the calf blood peptide composition has good effects of improving intestinal environment and relieving constipation.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (10)
1. Application of calf blood peptide in preparing products for improving intestinal environment and/or relieving constipation; the product comprises a medicament or a food product.
2. The use of claim 1, wherein said relieving constipation comprises:
(I) Accelerating gastric emptying; and/or
(II) accelerating intestinal peristalsis; and/or
(III) accelerating the first defecation time; and/or
(IV) increasing total defecation; and/or
(V) improving the water content of the excrement.
3. The use according to claim 1 or 2, wherein the method of preparing calf blood peptide comprises the steps of:
step (1): collecting calf blood, crushing blood cells in the calf blood, and mixing with blood plasma in the calf blood to obtain a hemoglobin mixed solution;
step (2): mixing the hemoglobin mixed solution obtained in the step (1) with papain, stirring, hydrolyzing, heating and preserving heat to obtain a primary enzymolysis solution, mixing the primary enzymolysis solution with flavourzyme, hydrolyzing, heating and preserving heat, filtering and concentrating to obtain the calf blood peptide.
4. A composition, characterized by comprising: calf blood peptide, auricularia, bulbus Allii Cepae and herba Spinaciae, and acceptable adjuvants.
5. The composition of claim 4, comprising: calf blood peptide, auricularia extract, bulbus Allii Cepae extract, herba Spinaciae extract, mel, citric acid and xylitol, and acceptable adjuvants.
6. The composition of claim 5, wherein each 1000g comprises, by weight:
7. use of a composition according to any one of claims 4 to 6 for the preparation of a product for improving the intestinal environment and/or alleviating constipation; the product comprises a medicament or a food product.
8. The use of claim 7, wherein said relieving constipation comprises:
(I) Accelerating gastric emptying; and/or
(II) accelerating intestinal peristalsis; and/or
(III) accelerating the first defecation time; and/or
(IV) increasing total defecation; and/or
(V) improving the water content of the excrement.
9. The use according to claim 7 or 8, wherein the method of preparing calf blood peptide in the composition comprises the steps of:
step (1): collecting calf blood, crushing blood cells in the calf blood, and mixing with blood plasma in the calf blood to obtain a hemoglobin mixed solution;
step (2): mixing the hemoglobin mixed solution obtained in the step (1) with papain, stirring, hydrolyzing, heating and preserving heat to obtain a primary enzymolysis solution, mixing the primary enzymolysis solution with flavourzyme, hydrolyzing, heating and preserving heat, filtering and concentrating to obtain the calf blood peptide.
10. A pharmaceutical or food product comprising a composition according to claim 4 or 5, together with acceptable adjuvants, adjuvants or additives.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211632071.4A CN116098983A (en) | 2022-12-19 | 2022-12-19 | Blood peptide composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211632071.4A CN116098983A (en) | 2022-12-19 | 2022-12-19 | Blood peptide composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116098983A true CN116098983A (en) | 2023-05-12 |
Family
ID=86255307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211632071.4A Pending CN116098983A (en) | 2022-12-19 | 2022-12-19 | Blood peptide composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116098983A (en) |
-
2022
- 2022-12-19 CN CN202211632071.4A patent/CN116098983A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110964650B (en) | Bacterial strain for preventing and treating metabolic diseases and application thereof | |
| JP5517215B2 (en) | Fermentation and culture method, plant fermented extract, plant fermented extract powder and blended plant fermented extract | |
| KR930002022B1 (en) | Process for the production of kefir yoghurt | |
| KR100813914B1 (en) | The conversion and modification of natural medicines by intestinal probiotics co-fermentation cultures | |
| CN105146614A (en) | Functional Chinese dwarf cherry seed ferment, ferment beverage and production method of ferment beverage | |
| CN110656151A (en) | Method for improving kidney-tonifying and yang-strengthening effects of sea cucumber | |
| CN101020715B (en) | Process of extracting and preparing deer nerve growth factor (DEER NGF) | |
| CN114891067B (en) | Dandelion anti-inflammatory active peptide and preparation method and application thereof | |
| CN112890064A (en) | Composite collagen peptide solid beverage and preparation method thereof | |
| CN1111949A (en) | Natural royal jelly tablet | |
| JP4132635B2 (en) | Uninactivated enzyme-enhanced composition | |
| CN105999210A (en) | Lucid-ganoderma active lactobacillus preparation and preparing method | |
| CN114214366A (en) | Compound medicine of small peptide powder and heme peptide red for preventing and treating anemia and preparation method and application thereof | |
| JPH02154693A (en) | Novel functional peptide and utilization thereof | |
| CN116726140A (en) | Shark liver peptide compound product for dispelling effects of alcohol and protecting liver and application thereof | |
| CN116098983A (en) | Blood peptide composition and application thereof | |
| CN114522183B (en) | Sea cucumber extract for increasing bone mineral density | |
| CN108771070B (en) | Compound functional beverage prepared by fermenting celery juice with eurotium cristatum, preparation method and application | |
| CN117050914B (en) | Acremonium muciniphilum and application thereof in improving GLP-1 secretion | |
| CN111778305B (en) | Spleen polypeptide composition for improving immunity and oral liquid | |
| CN108157974A (en) | A kind of placenta oligopeptides probiotics composite preparation and preparation method thereof | |
| CN110547446A (en) | royal jelly antioxidant peptide fruit enzyme and preparation method thereof | |
| CN118452281B (en) | Milk powder composition containing walnut peptide | |
| CN115005449B (en) | Compound natural plant protein nutritional meal after tumor operation and preparation method thereof | |
| CN111773375B (en) | Bone polypeptide composition and oral liquid for promoting bone growth and maintaining bone health |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |